Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects
Status:
Completed
Trial end date:
2018-05-22
Target enrollment:
Participant gender:
Summary
This was an open-label study that evaluated the safety, tolerability, and immunogenicity of
dose combinations of INO-1800 (DNA plasmids encoding Hepatitis B surface antigen [HBsAg] and
Hepatitis B core antigen [HBcAg]) and INO-9112 (DNA plasmid encoding human interleukin 12)
delivered by electroporation (EP) in 90 (ninety) nucleos(t)ide analogue treated participants.